EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 272 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel August 26, 2025 FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast... April 12, 2021 Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t... September 8, 2020 Load more HOT NEWS Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer Tovorafenib Approved for Some Children with Low-Grade Glioma 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung...
